Literature DB >> 33407739

NK cell-based cancer immunotherapy: from basic biology to clinical development.

Sizhe Liu1, Vasiliy Galat2,3,4, Yekaterina Galat4,5, Yoo Kyung Annie Lee6, Derek Wainwright7, Jennifer Wu8.   

Abstract

Natural killer (NK) cell is a specialized immune effector cell type that plays a critical role in immune activation against abnormal cells. Different from events required for T cell activation, NK cell activation is governed by the interaction of NK receptors with target cells, independent of antigen processing and presentation. Due to relatively unsophisticated cues for activation, NK cell has gained significant attention in the field of cancer immunotherapy. Many efforts are emerging for developing and engineering NK cell-based cancer immunotherapy. In this review, we provide our current understandings of NK cell biology, ongoing pre-clinical and clinical development of NK cell-based therapies and discuss the progress, challenges, and future perspectives.

Entities:  

Keywords:  Cancer immunotherapy; Clinical trials; NK cell; iPSC

Mesh：

Year:  2021        PMID： 33407739      PMCID： PMC7788999          DOI： 10.1186/s13045-020-01014-w

Source DB:  PubMed          Journal:  J Hematol Oncol        ISSN： 1756-8722            Impact factor:   17.388


  150 in total

1.  An Antibody Designed to Improve Adoptive NK-Cell Therapy Inhibits Pancreatic Cancer Progression in a Murine Model.

Authors:  Jaemin Lee; Tae Heung Kang; Wonbeak Yoo; Hyunji Choi; Seongyea Jo; Kyungsu Kong; Sang-Rae Lee; Sun-Uk Kim; Ji-Su Kim; Duck Cho; Janghwan Kim; Jeong-Yoon Kim; Eun-Soo Kwon; Seokho Kim
Journal:  Cancer Immunol Res       Date:  2018-12-04       Impact factor: 11.151

Review 2.  Natural killer cell memory in infection, inflammation and cancer.

Authors:  Adelheid Cerwenka; Lewis L Lanier
Journal:  Nat Rev Immunol       Date:  2016-01-25       Impact factor: 53.106

Review 3.  A view of human haematopoietic development from the Petri dish.

Authors:  Andrea Ditadi; Christopher M Sturgeon; Gordon Keller
Journal:  Nat Rev Mol Cell Biol       Date:  2016-11-23       Impact factor: 94.444

4.  Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma.

Authors:  Nina Shah; Li Li; Jessica McCarty; Indreshpal Kaur; Eric Yvon; Hila Shaim; Muharrem Muftuoglu; Enli Liu; Robert Z Orlowski; Laurence Cooper; Dean Lee; Simrit Parmar; Kai Cao; Catherine Sobieiski; Rima Saliba; Chitra Hosing; Sairah Ahmed; Yago Nieto; Qaiser Bashir; Krina Patel; Catherine Bollard; Muzaffar Qazilbash; Richard Champlin; Katy Rezvani; Elizabeth J Shpall
Journal:  Br J Haematol       Date:  2017-03-14       Impact factor: 6.998

5.  A novel CD7 chimeric antigen receptor-modified NK-92MI cell line targeting T-cell acute lymphoblastic leukemia.

Authors:  Fengtao You; Yinyan Wang; Licui Jiang; Xuejun Zhu; Dan Chen; Lei Yuan; Gangli An; Huimin Meng; Lin Yang
Journal:  Am J Cancer Res       Date:  2019-01-01       Impact factor: 6.166

6.  Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population.

Authors:  K Imai; S Matsuyama; S Miyake; K Suga; K Nakachi
Journal:  Lancet       Date:  2000-11-25       Impact factor: 79.321

7.  Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process.

Authors:  Jan Spanholtz; Frank Preijers; Marleen Tordoir; Carel Trilsbeek; Jos Paardekooper; Theo de Witte; Nicolaas Schaap; Harry Dolstra
Journal:  PLoS One       Date:  2011-06-16       Impact factor: 3.240

8.  Cancer-associated fibroblast-secreted CXCL16 attracts monocytes to promote stroma activation in triple-negative breast cancers.

Authors:  Roni Allaoui; Caroline Bergenfelz; Sofie Mohlin; Catharina Hagerling; Kiarash Salari; Zena Werb; Robin L Anderson; Stephen P Ethier; Karin Jirström; Sven Påhlman; Daniel Bexell; Balázs Tahin; Martin E Johansson; Christer Larsson; Karin Leandersson
Journal:  Nat Commun       Date:  2016-10-11       Impact factor: 14.919

9.  Ex vivo-expanded highly purified natural killer cells in combination with temozolomide induce antitumor effects in human glioblastoma cells in vitro.

Authors:  Yoshitaka Tanaka; Tsutomu Nakazawa; Mitsutoshi Nakamura; Fumihiko Nishimura; Ryosuke Matsuda; Koji Omoto; Yoichi Shida; Toshiharu Murakami; Ichiro Nakagawa; Yasushi Motoyama; Hiromichi Morita; Takahiro Tsujimura; Hiroyuki Nakase
Journal:  PLoS One       Date:  2019-03-06       Impact factor: 3.240

Review 10.  NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy.

Authors:  Wei Wang; Amy K Erbe; Jacquelyn A Hank; Zachary S Morris; Paul M Sondel
Journal:  Front Immunol       Date:  2015-07-27       Impact factor: 7.561
View more
  65 in total

Review 1.  Revisiting the HIF switch in the tumor and its immune microenvironment.

Authors:  Sophie J Cowman; Mei Yee Koh
Journal:  Trends Cancer       Date:  2021-11-04

2.  Targeted immunotherapy of triple-negative breast cancer by aptamer-engineered NK cells.

Authors:  Zhenghu Chen; Zihua Zeng; Quanyuan Wan; Xiaohui Liu; Jianjun Qi; Youli Zu
Journal:  Biomaterials       Date:  2021-11-15       Impact factor: 12.479

3.  Differential IL-12 signaling induces human natural killer cell activating receptor-mediated ligand-specific expansion.

Authors:  Avishai Shemesh; Harry Pickering; Kole T Roybal; Lewis L Lanier
Journal:  J Exp Med       Date:  2022-06-27       Impact factor: 17.579

4.  The Combination of Radiotherapy and Complement C3a Inhibition Potentiates Natural Killer cell Functions Against Pancreatic Cancer.

Authors:  Quaovi H Sodji; Dhanya K Nambiar; Vignesh Viswanathan; Rie von Eyben; Deana Colburg; Michael S Binkley; Caiyun G Li; Monica M Olcina; Daniel T Chang; Quynh-Thu Le; Amato J Giaccia
Journal:  Cancer Res Commun       Date:  2022-07-27

Review 5.  Enhancing a Natural Killer: Modification of NK Cells for Cancer Immunotherapy.

Authors:  Rasa Islam; Aleta Pupovac; Vera Evtimov; Nicholas Boyd; Runzhe Shu; Richard Boyd; Alan Trounson
Journal:  Cells       Date:  2021-04-29       Impact factor: 6.600

6.  Radium-223 dichloride causes transient changes in natural killer cell population and cytotoxic function.

Authors:  Calvin N Leung; Donna M Howell; Roger W Howell
Journal:  Int J Radiat Biol       Date:  2021-08-17       Impact factor: 3.352

Review 7.  Immunosuppressive Effects of Myeloid-Derived Suppressor Cells in Cancer and Immunotherapy.

Authors:  Mithunah Krishnamoorthy; Lara Gerhardt; Saman Maleki Vareki
Journal:  Cells       Date:  2021-05-11       Impact factor: 6.600

Review 8.  NK Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications.

Authors:  Paolo Sportoletti; Filomena De Falco; Beatrice Del Papa; Stefano Baldoni; Valerio Guarente; Andrea Marra; Erica Dorillo; Chiara Rompietti; Francesco Maria Adamo; Loredana Ruggeri; Mauro Di Ianni; Emanuela Rosati
Journal:  Int J Mol Sci       Date:  2021-06-22       Impact factor: 5.923

Review 9.  Optimizing NK Cell-Based Immunotherapy in Myeloid Leukemia: Abrogating an Immunosuppressive Microenvironment.

Authors:  Natasha Mupeta Kaweme; Fuling Zhou
Journal:  Front Immunol       Date:  2021-06-17       Impact factor: 7.561

10.  Challenges and next steps in the advancement of immunotherapy: summary of the 2018 and 2020 National Cancer Institute workshops on cell-based immunotherapy for solid tumors.

Authors:  Laura K Fogli; Rosemarie Aurigemma; Connie L Sommers; Anju Singh; Kasia Bourcier; Marc S Ernstoff
Journal:  J Immunother Cancer       Date:  2021-07       Impact factor: 13.751
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.